Assessment of Vascular Complications in Patients Undergoing Peripheral Revascularization and the Impact of SGLT-2 Inhibitors

What this Trial Is About

This research aims to assess how sodium-glucose co-transporter 2 inhibitors (SGLT2-i) affect vascular complications in patients with peripheral arterial disease (PAD) who have undergone lower limb revascularization procedures. The study compares patients who were treated with SGLT2 inhibitors during the year after surgery to those who were not, focusing on cardiovascular and limb-related events. It is an observational study conducted by Wroclaw Medical University, monitoring outcomes over one year. Patients included are those who had either open or minimally invasive vascular surgery for acute or chronic ischemia. The study observes two groups: those treated with SGLT2 inhibitors such as empagliflozin, dapagliflozin, or canagliflozin during the 12 months following the procedure, and those who did not receive these medications. Treatment is not assigned by the study but occurs as part of routine care. The observation period includes assessments at 30 days, 3 months, and 1 year post-procedure. Participants are contacted by phone to report any major adverse cardiovascular events (MACE) like heart attacks, strokes, or cardiovascular death, and major adverse limb events (MALE) such as vessel restenosis, reinterventions, or amputations. Demographic and clinical data are collected from medical records. Researchers compare the number of these events between the treated and untreated groups during the year following surgery to better understand the impact of SGLT2 inhibitors on vascular outcomes.

Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors